

April 30, 2021

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Outcome of the Board Meeting held on April 30, 2021

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. April 30, 2021, inter alia, has considered and unanimously:

- 1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. Copy of the same is enclosed along with the Report of the Auditors thereon and a declaration stating that the said report is with unmodified opinion.
- Recommended equity dividend of Rs. 7.20 per share of Rs. 8/- each (90%) for the financial year ended March 31, 2021, which will be paid to the shareholders within 30 days of declaration of the same at the ensuing Annual General Meeting.
- 3. As per recommendation of the Nomination and Remuneration Committee, approved the following, subject to approval of the shareholders at the ensuing Annual General Meeting:





- a) Re-appointment of Mr. Yugal Sikri (DIN:07576560) as the Managing Director of the Company for a period from October 1, 2021 to April 30, 2024.
- b) Re-appointment of Ms. Zahabiya Khorakiwala (DIN:00102689) as an Independent Director of the Company for a second term of 5 (five) consecutive years from July 27, 2021 to July 26, 2026.
- 4. Approved the Audited Financial Statements of the Company, for the year ended March 31, 2021.

Profiles of Mr. Sikri and Ms. Khorakiwala are attached herewith as Annexure A.

The Board meeting commenced at 3:00 p.m. and concluded at 06:00 p.m.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited

Rhisanderar

Rajesh Shirambekar Head – Legal & Company Secretary

Encl.: as above





Annexure A

Sr.	Details of events that needs	Information of such events
No	to be provided	
1.	Reason for change viz.	Re-appointment
	appointment, resignation,	
	removal, death or otherwise	
2.	Date of Appointment	Date of Re-appointment:
	/Cessation (as applicable)	• Re-appointment of Mr. Yugal Sikri as the Managing
	Term of Appointment	Director of the Company from October 1, 2021.
		• Re-appointment of Ms. Zahabiya Khorakiwala as an
		Independent Director of the Company from July 27,
		2021.
		Term of Re-appointment:
		• Mr. Sikri has been re-appointed for a period from
		October 1, 2021 to April 30, 2024 subject to
		approval of shareholders at the ensuing Annual
		General Meeting.
		• Ms. Khorakiwala has been re-appointed for a period
		of 5 (five) consecutive years from July 27, 2021 to
		July 26, 2026 subject to approval of shareholders at
		the ensuing Annual General Meeting
3.	Brief Profiles (in case of	Mr. Sikri
	appointment)	Mr. Sikri is a Senior Pharma Industry Professional with
		rich and diverse experience in the pharmaceutical
		industry. Mr. Sikri is responsible for the overall
		conduct and management of the business and affairs
		of the Company. This includes broad development of
		domestic and international business; providing
		strategic direction to the three business units of the





Company; review of product portfolio in light of patent laws and continual introduction of new products; enhancement of manufacturing efficiencies and rationalization of costs. Mr. Sikri has successfully handled and overlooked domestic and international business for reputed companies like GlaxoSmithKline, Warner Lambert/ Pfizer, Novartis, Ranbaxy and RPGLS for many years. He is also an Independent Director on the Board of AIC-NMIMS Incubation Centre.

Ms. Khorakiwala

Ms. Zahabiya Khorakiwala is the Managing Director of Wockhardt Hospitals, a chain of new-age multi super speciality Hospitals.

Greatly inspired by her father, Ms. Khorakiwala started her Journey with Wockhardt Hospitals as Director, Business Development in 2007 and assumed the mantle of Managing Director in 2010. Under her stewardship Wockhardt Hospitals with eight superspeciality hospitals, has emerged as country's foremost patient centric and innovative healthcare destination globally. She has augmented Wockhardt Hospitals' robust portfolio of hospitals in tier-II cities by setting up two new hospitals in Mumbai. The ultramodern guaternary care South Mumbai Hospital that she built from scratch, received the accreditation from the coveted JCI (Joint Commission International) within first 3 years of its operation, an unparalleled feat in Indian Healthcare Industry. She has also set up Wockhardt Global School, a state-of-the-art K-12 school with International Baccalaureate & CBSE





		programmes in Aurangabad.
		Ms. Khorakiwala has been recognised as India's "Forty under Forty" emerging business leader and one
		of the Corporate India's fastest rising women leaders
		by Economic Times. She was also conferred with
		Young Business Woman Leader Award by Lions Club International and the Women Leadership in
		Healthcare Award by ABP News.
		Schooled at the prestigious Aiglon College in Switzerland, she went on to study Psychology at New
		York University and later received an MBA degree
		from the Indian School of Business.
		Ms. Khorakiwala strongly believes in "the power of Calm" i.e. to maintain grace under pressure,
		overcome challenges, learn from setbacks and focus on goals. She considers knowledge, courage and
		imagination as the three most important drivers for
		success.
4.	Disclosure of Relationship	Mr. Yugal Sikri and Ms. Zahabiya Khorakiwala are not
	between Directors (in case of	related to any Director or Key Managerial Personnel of
	appointment of a Director)	the Company.
5.	Affirmation	Based on the information available with the Company,
		Mr. Yugal Sikri and Ms. Zahabiya Khorakiwala are not
		debarred from holding the office of Directors by virtue
		of any SEBI order or any other such authority.

